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ABSTRACT 
Objective: We aim to reveal real world data according to clinical presentations, 
radiological findings and treatment results of high flow vascular malformations of the 
lower extremity among patients in the AVM Register. 
Methods: We included all patients presenting with high flow malformations of the 
lower limb who were treated in Inselspital from 2008 to 2018; demographics, clinical 
presentations, radiological data, laboratory findings as well as interventional 
treatment including outcomes were analyzed. We compared patients with solely 
arteriovenous malformations with those presenting Parkes Weber Syndrome in terms 
of symptoms and therapy results separately.  
Results: 31 Patients (16 women, 15 men) with a median age at the time of the first 
diagnosis of 27 years [range 10-33] and a median age of first presentation of 26 
years [8-30] were included. 22 patients (71%) presented solely Arteriovenous 
Malformation (AVM); nine were diagnosed with Parkes Weber Syndrome (PWS). The 
malformations were localized in the lower limb in 17 cases and in the foot in 19 cases. 
The most common symptoms were pain (n = 25; 80.6%) swelling (21; 67.7%) and soft 
tissue hypertrophy (13; 41.9%). PWS patients presented with significantly more 
recurrent bleedings (66.7% vs. 2.5% p<0.001), recurrent infections of the lower limb 
(44.4% vs. 4.55% p=0,017) and length difference of the lower extremity (55.6% vs. 
13.6% p=0.027). Laboratory tests revealed local intravascular coagulopathy in 
87.5% PWS patients with a median level of d-dimer of 17,256 μg/L (norm 
<500μg/L). The AVM group revealed normal d-dimer testing (median d-dimer 
322μg/L). Radiological findings showed an elevated net shunt volume in the femoral 
artery of median 700 ml/min [150 - 1100], and there was a significant difference 
between PWS and AVM group (1500 ml/min [1300 – 2800] vs. 400 ml/min [150 - 
950] p=0,011). In total, 16 patients (51%) underwent alcoholic embolization, three 
(9.7%) surgery and five (16.1%) mixed procedure. The treatment resulted in 
reduction of net shunt volume to a median level of 100 ml/min [0-300]; the median 
net shunt volume in the AVM group at the end of treatment was significantly lower at 
50 ml/min; however, the end flow volume in PWS group did not change. 
Nevertheless, therapy resulted in lowering of the d-dimer level in the PWS group at a 
mean level of 6063μg/L. 3 PWS and no AVM patient died as a result of the disease 
(33.3% vs. 0% p=0,019).  
Conclusions: There are common characteristic features among high flow 
malformations of the lower extremity which should evoke the diagnosis. Patients with 
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solely arteriovenous malformations without involvement of the 
capillary system can be effectively treated with intervention. 
Patients with Parkes Weber Syndrome present symptoms that 
are more serious and have a worse prognosis than those with 
AVM. New therapeutic approaches for treating this type of 
complex high flow malformation are needed.  
INTRODUCTION 
Congenital Vascular Malformations (CVM) is anomalies of 
blood and lymphatic vessels which develop due to deficient 
vasculogenesis in variable localizations secondary to sporadic 
gene mutations [1]. They are classified according to the 
International Society for the Study of Vascular Anomalies 
(ISSVA) [2]. As symptoms are complex and variable, congenital 
vascular malformations are considered rare diseases; data on 
the various types are vague and no standard treatment for 
CVM is established. Arteriovenous Malformations (AVM) and 
Arteriovenous Fistulas (AVF) are congenital and often do not 
provoke symptoms until they are large enough to cause 
hemodynamic disturbances. Progression can be triggered by 
environmental factors such as activity, trauma or hormonal 
changes as occurring during puberty or pregnancy [3]. They 
are most frequently localized in the head and neck, but can 
develop anywhere [4]. In this article we focus on high-flow 
vascular malformations of the lower limb with AVM and Parkes 
Weber Syndrome (PWS), comprising port wine stains, 
arteriovenous fistulas and limb overgrowth, which is extremely 
rare [5]. To provide best treatment for these patients, clinicians 
need a full understanding of the types of lesions, their natural 
history, appropriate diagnostic studies, and indication for 
treatment. Treatment options include surgery, embolization, 
laser, and pharmacotherapy, but representative cohorts are 
lacking [6-8]. Another problem is the heterogeneity of outcome 
measurements further complicating comparison of existing 
cohorts [9]. Several small exclusively Korean cohorts include 
AVM treatment of the foot (29 patients) [10], of the trunc and 
extremities (66 patients) [11] and of the hands (31 patients) 
[12]. The only non-Asian cohort consists of 272 patients with 
AVM of extracranial location treatedat Harvard Medical 
School, lacking demographic details as well as information on 
precise AVM location [5]. The Division of Angiology at the 
University Hospital of Bern treats patients with CVM since 2008 
and is the Swiss Reference Center for Vascular Malformations. 
METHODS 
Patients  
We included 31 Patients (15 men, 16 women) with a mean 
age of 30.5 years [range 10-73] at first consultation who were 
diagnosed or treated at University Hospital of Bern, 
Switzerland, between 2008 and 2018 for arteriovenous 
malformations - AVM (22 patients) or Parkes Weber Syndrome 
(9) of the lower limbs. 16 patients were treated previously: 
Seven with surgery only, nine underwent mixed procedure 
(sclerotherapy and/or alcohol embolization in combination with 
surgery). All patients signed general informed consent and the 
study was approved by Bernice Cantonal Ethics Committee as 
a part of AVM Registry.  
Procedures 
Since 2008, a special malformation counselling program, with 
a standardized diagnostic and therapeutic algorithm was 
established at the University Hospital of Bern. Patients undergo 
following steps: vascular assessment including Duplex 
Ultrasound (DUS) and flow volume measurement, followed by 
dynamic MRI-angiogram if interventional therapy is needed. 
Results are discussed by an interdisciplinary malformations’ 
board consisting of an angiologist, a plastic and a vascular 
surgeon, a dermatologist and a childrens’ oncologist. 
Interventional treatment options are percutaneous or retro-
venous alcohol embolization in repeated sessions every 4-6 
weeks with two control consultations at the first and 14th day 
after each procedure. If surgery is performed, patients are 
controlled after completing procedure. Standard examination 
consists of photographical and thermographic documentation, 
clinical examination as well as DUS. After treatment, patients 
are controlled every year.  
Medical record review 
Patients who attended our consultation and were diagnosed 
with AVM or PWS of the lower extremity were retrospectively 
reviewed. Initial clinical manifestation, medical history, 
laboratory parameters, and initial net shunt volume were 
extracted from the consultation reports. Further, we reviewed 
electronic medical records in terms of therapy type (surgery, 
alcohol embolization, laser therapy and conservative 
procedure), major complications (death, limb amputation), and 
final net volume shunt as well as laboratory findings. 
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Statistical considerations 
We used standard epidemiological descriptive methods to 
characterize the patient population and the classification of the 
malformations. Continuous variables are presented as median 
with lower and upper quartile, categorical variables as n (%). 
Effect sizes are presented as Hodges-Lehmann median 
difference or risk difference. Continuous variables are 
compared using Wilcoxon-Mann-Whitney tests, categorical 
variables using Fisher's exact test. 
Results 
In total, 31 patients (48, 4%male) with a median age of 37 
years [range 10-73] at first consultation were included. 22 
patients (71%) presented with arteriovenous malformations 
(AVM) solely; nine (29%) were diagnosed with Parkes Weber 
Syndrome (PWS) of the lower limbs. Median age at the time of 
the first diagnosis was 27 years [10-33] and median age of 
first presentation of 26 years [8-30]. First manifestation of 
PWS was earlier than AVM (15 [0-15] vs. 19 [10-30]p=0,11). 
The malformations were localized in the lower limb in 17 cases 
and in the foot in 19 cases as presented in Diagram 1.  
The most common symptoms were pain 25 (80.6%) swelling 
21(67.7%) and soft tissue hypertrophy 13 (41.9%). PWS 
patients presented with generally more symptoms (4.3 
symptoms per PWS patient vs. 2.4symptoms for AVM patient) 
and suffered significantly more recurrent bleedings (66.7% vs. 
2.5% p<0.001), recurrent infections of the lower limb (44.4% 
vs. 4.55% p=0.017) and length difference of the extremity 
(55.6% vs. 13.6% p=0.027). The rate of intolerance of 
physical exertion, overheat of the limb, varicose vein were  
similar in both groups. Initial symptoms are presented in Table 
1. Initial laboratory testing revealed Localized Intravascular 
Coagulopathy (LIC) in 87.5% PWS patients with a median 
level of d-dimer of 17,256 [6,185- 52,929μg/L] (norm 
<500μg/L). The AVM group revealed normal d-dimer testing 
(median d-dimer 322μg /L). Furthermore, chronic anemia was 
diagnosed in three PWS patients and none AVM patient (3 
(42.9%) vs. 0 p=0.013). 
Radiological findings showed an elevated net flow volume of 
median 700 ml/min [150-1100], and there was a significant 
difference between PWS and AVM group (1500 ml/min 
[1300-2800] vs. 400 ml/min [150-950] p= 0,011). Therapy 
was performed in 24 patients; 16 (51%) underwent repeated 
alcoholic embolization, three (9.7%) surgery and five (16.1%) 
mixed procedure (sclerotherapy and/or alcohol embolization 
in combination with surgery). Different reasons led to 
conservative, noninvasive therapy: continuing the treatment in 
other hospitals (2), small, asymptomatic lesions (2), 
malformations of solely type IV (intestinal) (1) and patients 
preferences (2). The treatment resulted in reduction of net shunt 
volume to a median level of 100 ml/min [0-300]; the median 
net shunt volume in the AVM group with a level of 50 ml/min 
was significantly lower at the end of the treatment; however, 
theflow volume in PWS group didn’t change (1500ml/min 
[1500-8100]). Nevertheless, therapy resulted in lowering of 
the d-dimer level in the PWS group to 6,063µg/L. 3 PWS and 
no AVM patient died as a result of the disease (33.3% vs. 0% 
p=0.019).  
 
 
 
 
 
 
 
 
 
 
 
Diagram 1: Localization of the malformation. 
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CONCLUSIONS  
A description of high flow vascular malformations affecting the 
lower extremities of Caucasians was lacking in the international 
literature. Our patients’ population represents a sample of 
specific symptoms with pain, swelling and soft tissue 
hypertrophy that should alarm physicians to screen for AVM. 
Although there are some studies describing AVM of the lower 
extremity [10,11], we conducted the first study to compare 
clinical presentation and therapy outcomes of AVM and 
Parkers Weber Syndrome (PWS) of the lower extremities in a 
Caucasian cohort. These two conditions, despite hemodynamic 
and clinical similarities, have profound pathophysiologic 
differences, which critically influence the outcomes. Therefore, 
we suggest performing diagnostic and therapeutic procedures 
in specialized centers. Our experience in treatment of the AVM 
is similar to the results of international acknowledged centers of 
vascular malformations with an interdisciplinary approach 
[6,10]. In this setting AVM patients can be treated safely and 
effectively. We propose a primarily percutaneous or 
transvenous approach using 96% alcohol and coil embolization 
to occlude AVM. Some centers use particles [13] or other 
substances for occluding the nidus with variable effects [14]. 
Surgical excision may be performed depending on location 
and extension of AVM primarily or secondarily after 
embolization. 
In accordance to international reports, our experience shows  
 
 
 
poor prognosis of interventional PWS treatment; available 
case reports and one case series of ten children [15] report 
symptom-oriented treatment with short-term follow up. Long-
term effects remain unclear [16]. PWS due to high flow 
component is a progressive illness. Since the older age of our 
patients (mean 18 years), symptoms were more serious and 
courses more dramatic. We still did not find a cure for the 
progressive nature of this illness; embolization and other 
invasive procedures seem to temporarily slow down the course. 
Single reports show promising effects of new pharmacological 
approaches using the mTOR-inhibitor Sirolimus [17], but further 
studies are needed in this field. 
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